ClinicalTrials.gg
CompletedNCT02854605Updated Jan 29, 2019Results posted

Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)

A Phase 2 interventional study of GS-9674 and Placebo to match GS-9674 in Nonalcoholic Steatohepatitis (NASH), sponsored by Gilead Sciences. Completed at 37 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-01-29.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Gilead Sciences.

Enrollment
9th of 16
140 · median 161
Started
2016
with 5 others
Phase 2
11 of 16
none open now
Registered
8th of 16
by date

Among the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences, this one is the 9th largest by enrollment, is one of 6 that started in 2016, is one of 11 in phase 2, and was the 8th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

None of the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences as a file.
02

Study summary

The primary objective of this study is to evaluate the safety and tolerability of GS-9674 in participants with nonalcoholic steatohepatitis (NASH).

03

Conditions studied

  • Nonalcoholic Steatohepatitis (NASH)

Keywords

  • Non-alcoholic fatty liver disease (NAFLD)
  • Fibrosis
  • GS-9674
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Meets the following conditions:

    • A clinical diagnosis of nonalcoholic fatty liver disease (NAFLD)
    • Screening magnetic resonance imaging - proton density fat fraction (MRI-PDFF) with ≥ 8% steatosis
    • Screening magnetic resonance elastography (MRE) with liver stiffness ≥ 2.5 kilopascal (kPa) OR
    • A historical liver within 12 months of screening consistent with NASH with fibrosis, but not cirrhosis, and
    • No documented weight loss > 5% between the date of the liver biopsy and screening.
  • count ≥ 150,000/mm\^3
  • Albumin ≥ 3.3 g/dL
  • Serum creatinine ≤ (ULN)

Key Exclusion Criteria:

  • Pregnant or lactating females
  • (ALT) > 5x upper limit of the normal range (ULN)
  • Other causes of liver disease including , viral, and alcoholic liver disease
  • Cirrhosis of the liver

    • Prior history of decompensated liver disease, including ascites, hepatic encephalopathy, or variceal bleeding
  • (BMI) \< 18 kg/m\^2
  • Uncontrolled diabetes mellitus ( > 9% at screening)
  • (INR) > 1.2 unless on anticoagulant therapy
  • Total > 1 x ULN, except with diagnosis of Gilbert's syndrome

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    GS-9674 30 mg

    GS-9674 30 mg + placebo to match GS-9674 100 mg for 24 weeks

    Drug: GS-9674 · Drug: Placebo to match GS-9674

  • Experimental
    GS-9674 100 mg

    GS-9674 100 mg + placebo to match GS-9674 30 mg for 24 weeks

    Drug: GS-9674 · Drug: Placebo to match GS-9674

  • Placebo comparator
    Placebo

    Placebo to match GS-9674 30 mg + placebo to match GS-9674 100 mg for 24 weeks

    Drug: Placebo to match GS-9674

Interventions

  • Tablet administered orally once daily

  • DrugPlacebo to match GS-9674

    Tablet(s) administered orally once daily

06

What researchers measure

Primary outcomes

  1. Overall Safety of GS-9674 as Assessed By Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

    TEAEs were defined as 1 or both of the following: 1) Any adverse events (AE) with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug, 2) Any AEs leading to premature discontinuation of study drug.

    Time frame: Up to 24 weeks plus 30 days

  2. Overall Safety of GS-9674 as Assessed By Percentage of Participants With Treatment-Emergent Laboratory Abnormalities

    Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any post-baseline time point, up to and including the date of last dose of study drug plus 30 days for participants who permanently discontinued study.

    Time frame: Up to 24 weeks plus 30 days

07

Results

Posted Jan 29, 2019

Participant flow

Participants were enrolled at study sites in North America, Hong Kong, New Zealand, and Europe. The first participant was screened on 26 October 2016. The last study visit occurred on 09 January 2018.

Participant flow — Overall Study
MilestoneGS-9674 100 mgGS-9674 30 mgPlacebo
Started565628
Completed534924
Not completed374
Withdrew: Adverse event152
Withdrew: Lost to follow-up020
Withdrew: Withdrew consent101
Withdrew: Investigator's discretion100
Withdrew: Protocol violation001

Outcome measures

PrimaryOverall Safety of GS-9674 as Assessed By Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

TEAEs were defined as 1 or both of the following: 1) Any adverse events (AE) with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug, 2) Any AEs leading to premature discontinuation of study drug.

Time frame:
Up to 24 weeks plus 30 days
Reported as:
Number · Percentage of participants
Overall Safety of GS-9674 as Assessed By Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
Percentage of participantsGS-9674 100 mgGS-9674 30 mgPlacebo
TEAEs89.376.867.9
TEAEs leading to premature discontinuation of drug1.88.97.1
PrimaryOverall Safety of GS-9674 as Assessed By Percentage of Participants With Treatment-Emergent Laboratory Abnormalities

Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any post-baseline time point, up to and including the date of last dose of study drug plus 30 days for participants who permanently discontinued study.

Time frame:
Up to 24 weeks plus 30 days
Reported as:
Number · Percentage of participants
Overall Safety of GS-9674 as Assessed By Percentage of Participants With Treatment-Emergent Laboratory Abnormalities
Percentage of participantsGS-9674 100 mgGS-9674 30 mgPlacebo
Any Grade ≥ 189.392.992.9
Grade 135.742.950.0
Grade 237.537.525.0
Grade 37.110.714.3
Grade 48.91.83.6

Adverse events

Collected over Up to 24 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GS-9674 100 mg0/56 (0%)2/56 (3.6%)39/56 (69.6%)
GS-9674 30 mg0/56 (0%)2/56 (3.6%)34/56 (60.7%)
Placebo0/28 (0%)1/28 (3.6%)17/28 (60.7%)
Most frequent serious events
Most frequent serious events
EventGS-9674 100 mgGS-9674 30 mgPlacebo
Hypertensive crisisVascular disorders0/560/561/28
Bile duct stoneHepatobiliary disorders1/560/560/28
Oesophageal carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/560/560/28
B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/561/560/28
Thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/561/560/28
Pelvic painReproductive system and breast disorders0/561/560/28
Most frequent other events
Showing 10 of 26
Most frequent other events
EventGS-9674 100 mgGS-9674 30 mgPlacebo
PruritusSkin and subcutaneous tissue disorders13/569/565/28
HeadacheNervous system disorders4/566/564/28
FatigueGeneral disorders2/567/561/28
Abdominal distensionGastrointestinal disorders2/563/563/28
NasopharyngitisInfections and infestations1/563/563/28
Upper respiratory tract infectionInfections and infestations6/565/562/28
Back painMusculoskeletal and connective tissue disorders2/564/563/28
Abdominal painGastrointestinal disorders5/562/560/28
Abdominal pain upperGastrointestinal disorders3/565/561/28
DepressionPsychiatric disorders1/565/560/28

Baseline characteristics

Safety Analysis Set included all participants who took at least 1 dose of study drug.

Age, Continuous
Age, Continuous(Years)GS-9674 100 mgGS-9674 30 mgPlaceboTotal
Mean55 ± 10.551 ± 12.850 ± 9.953 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)GS-9674 100 mgGS-9674 30 mgPlaceboTotal
Female35371587
Male21191353
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)GS-9674 100 mgGS-9674 30 mgPlaceboTotal
Hispanic or Latino1719844
Not Hispanic or Latino39372096
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GS-9674 100 mgGS-9674 30 mgPlaceboTotal
Race, Customized — American Indian or Alaska Native0112
Race, Customized — Asian135422
Race, Customized — Native Hawaiian or Other Pacific Islander0202
Race, Customized — Black or African American1113
Race, Customized — White424721110
Race, Customized — Other0011
Region of Enrollment
Region of Enrollment(Participants)GS-9674 100 mgGS-9674 30 mgPlaceboTotal
New Zealand1214
Canada127625
Hong Kong52310
United States37431696
United Kingdom1001
Switzerland0224
08

Study locations

37 sites
  • Ruane Clinical Research Group Inc.
    Los Angeles, California 90036, United States
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
  • Inland Empire Liver Foundation
    Rialto, California 92377, United States
  • Clinical Research of South Florida
    Coral Gables, Florida 33134, United States
  • Atlanta Gastroenterology Associates
    Atlanta, Georgia 30308, United States
  • Northwestern Memorial Hospital, Clinical Research Unit
    Chicago, Illinois 60611, United States
  • Crescent Clinical Research Center, LLC
    Metairie, Louisiana 70006, United States
  • Tulane University Health Sciences Center
    New Orleans, Louisiana 70112, United States
  • Kansas City Research Institute
    Kansas City, Missouri 64131, United States
  • Concorde Medical Group, PLLC
    New York, New York 10016, United States
  • Duke University Medical Center, Duke South Clinics
    Durham, North Carolina 27710, United States
  • Carolinas Center for Liver Disease/Carolinas HealthCare System
    Durham, North Carolina 28078, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Gastro One
    Germantown, Tennessee 38138, United States
  • Quality Medical Research, PC
    Nashville, Tennessee 37211, United States
  • Texas Clinical Research Institute
    Arlington, Texas 76012, United States
  • The Liver Institute at Methodist Dallas Medical Center
    Dallas, Texas 75203, United States
  • Texas Digestive Disease Consultants
    Dallas, Texas 75246, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • Pinnacle Clinical Research
    Live Oak, Texas 78233, United States
  • American Research Corporation at the Texas Liver Institute
    San Antonio, Texas 78215, United States
  • Intermountain Liver Disease and Transplant Center
    Murray, Utah 84107, United States
  • Bon Secours St. Mary's Hospital of Richmond, Inc d/b/a Bon Secours Liver Institute of Virginia
    Newport News, Virginia 23602, United States
  • Bon Secours St. Mary's Hospital of Richmond, Inc. d/b/a Bon Secours Liver Institute of Virginia
    Richmond, Virginia 23226, United States
  • McGuire VA Medical Center
    Richmond, Virginia 23249, United States
  • Swedish Organ Transplant and Liver Center
    Seattle, Washington 98104, United States
  • University of Calgary
    Calgary, Alberta T2N 4Z6, Canada
  • LMC Clinical Research Inc (Bayview)
    Toronto, Ontario M4G 3E8, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G 2C4, Canada
  • Toronto Liver Center
    Toronto, Ontario M6H 3M1, Canada
  • Toronto Digestive Disease Associates, Inc.
    Vaughan, Ontario L4L 4Y7, Canada
  • Princess Margaret Hospital
    Kowloon, Hong Kong
  • The Chinese University of Hong Kong
    Sha Tin, Hong Kong
  • Auckland Clinical Studies
    Auckland, 1010, New Zealand
  • Universitatsspital Bern, Inselspital, Universitatsklinik fur Viszerale Chirurgie und Medizin, Hepatologie
    Bern, 3010, Switzerland
  • Universitatsspital Zurich
    Zurich, CH-8091, Switzerland
  • Addenbrooke's Hospital
    Cambridge, CB2 0QQ, United Kingdom
09

References and documents

Publications

  • Patel K, Harrison SA, Elkhashab M, Trotter JF, Herring R, Rojter SE, Kayali Z, Wong VW, Greenbloom S, Jayakumar S, Shiffman ML, Freilich B, Lawitz EJ, Gane EJ, Harting E, Xu J, Billin AN, Chung C, Djedjos CS, Subramanian GM, Myers RP, Middleton MS, Rinella M, Noureddin M. Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial. Hepatology. 2020 Jul;72(1):58-71. doi: 10.1002/hep.31205. PubMed 32115759 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in Jan 2018, 14 months.

Results were first posted in Jan 2019, 1 year after primary completion.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 14 months is below that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2016
First posted
Aug 3, 2016
StartActual
Oct 26, 2016
Primary completionActual
Jan 9, 2018
CompletionActual
Jan 9, 2018
Results first posted
Jan 29, 2019
Last update
Jan 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02854605
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Aug 3, 2016
Start date
Oct 26, 2016
Primary completion
Jan 9, 2018
Completion
Jan 9, 2018
Results posted
Jan 29, 2019
Last update
Jan 29, 2019

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cilofexor

Start the discussion